Revisiting Roles of Health Technology Assessment on Drug Policy in Universal Health Coverage in Thailand: Where Are We? And What Is Next?

被引:10
|
作者
Tanvejsilp, Pimwara [1 ]
Taychakhoonavudh, Suthira [2 ]
Chaikledkaew, Usa [3 ,4 ]
Chaiyakunapruk, Nathorn [5 ,6 ,7 ,8 ]
Ngorsuraches, Surachat [9 ]
机构
[1] Prince Songkla Univ, Fac Pharmaceut Sci, Dept Pharm Adm, Hat Yai, Songkhla, Thailand
[2] Chulalongkorn Univ, Fac Pharmaceut Sci, Bangkok, Thailand
[3] Mahidol Univ, Fac Pharm, Dept Pharm, Social Adm Pharm Excellence Res Unit, Bangkok, Thailand
[4] Mahidol Univ, Hlth Technol Assessment Postgrad Program, Bangkok, Thailand
[5] Monash Univ Malaysia, Sch Pharm, Subang Jaya, Selangor, Malaysia
[6] Naresuan Univ, Fac Pharmaceut Sci, Ctr Pharmaceut Outcomes Res, Dept Pharm Practice, Phitsanulok, Thailand
[7] Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA
[8] Monash Univ Malaysia, Asian Ctr Evidence Synth Populat Implementat & Cl, Hlth & Well Being Cluster, Global Asia 21st Century Platform, Subang Jaya, Selangor, Malaysia
[9] Auburn Univ, Dept Hlth Outcomes Res & Policy, Harrison Sch Pharm, 037 James E Foy Hall, Auburn, AL 36849 USA
关键词
drug policy; health technology assessment; Thailand; universal health coverage;
D O I
10.1016/j.vhri.2018.11.004
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: To describe the process, challenges, and future direction of health technology assessment (HTA), focusing on the drug selection of the National List of Essential Medicines (NLEM) in Thailand. Methods: Literature and government documents were reviewed and analyzed by authors with experiences in HTA and drug policy in the country. Results: The structure of HTA and its process in the drug selection of the NLEM were described, followed by the outcomes of the use of HTA. Examples of lowering drug prices, as a result of price negotiation using HTA, were presented. A few examples were also provided to demonstrate how decisions were made from considering factors beyond cost-effectiveness findings. Finally, challenges on various issues including improvement of HTA structure and process were discussed for the future direction of HTA in Thailand. Conclusions: HTA has been adopted as a tool for the drug selection of the NLEM to help Thailand achieve universal health coverage. Nevertheless, various challenge sexist and need to be addressed.
引用
收藏
页码:78 / 82
页数:5
相关论文
共 50 条
  • [31] Nephrology Advanced Practice Registered Nurse Health Policy: Where Are We? What Is Our Future?
    Kao, Yeewan Sum
    NEPHROLOGY NURSING JOURNAL, 2015, 42 (03) : 289 - 293
  • [32] Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis
    Rattanavipapong, Waranya
    Anothaisintawee, Thunyarat
    Teerawattananon, Yot
    PLOS ONE, 2018, 13 (02):
  • [33] Unpacking the process of developing South Africa's national drug policy - lessons for universal health coverage
    Gray, Andrew L.
    Suleman, Fatima
    JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE, 2024, 17 (01)
  • [34] A difficult balancing act: Policy actors' perspectives on using economic evaluation to inform health-care coverage decisions under the universal health insurance coverage scheme in Thailand
    Teerawattananon, Yot
    Russell, Steve
    VALUE IN HEALTH, 2008, 11 : S52 - S60
  • [35] Assessing the Implementation of Public Service Contracting in the Universal Health Coverage Policy in Indonesia, the Philippines, and Thailand: The Government Tools Approach
    Trairatananusorn, Ruechagorn
    ASR CHIANG MAI UNIVERSITY JOURNAL OF SOCIAL SCIENCES AND HUMANITIES, 2022, 9 (02):
  • [36] Socioeconomic inequality in self-reported oral health status: The experience of Thailand after implementation of the Universal Coverage policy
    Somkotra, T.
    COMMUNITY DENTAL HEALTH, 2011, 28 (02) : 136 - 142
  • [37] What we need is health system transformation and not health system strengthening for universal health coverage to work: Perspectives from a National Health Insurance pilot site in South Africa
    Michel, Janet
    Obrist, Brigit
    Barnighausen, Till
    Tediosi, Fabrizio
    Di McIntyre
    Evans, David
    Tanner, Marcel
    SOUTH AFRICAN FAMILY PRACTICE, 2020, 62 (01) : 1 - 15
  • [38] Burning Issues in Health Technology Assessment and Policy Making: What's Keeping Senior Health Technology Assessment Users and Producers up at Night?
    Trowman, Rebecca
    Ollendorf, Daniel A.
    Sampietro-Colom, Laura
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2020, 36 (01) : 5 - 7
  • [39] Economic evaluations conducted by Canadian health technology assessment agencies: Where do we stand?
    Tarride, Jean-Eric
    McCarron, Catherine Elizabeth
    Lim, Morgan
    Bowen, James M.
    Blackhouse, Gord
    Hopkins, Robert
    O'Reilly, Daria
    Xie, Feng
    Goeree, Ron
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2008, 24 (04) : 437 - 444
  • [40] Health Technology Assessment and Evidence-Based Medicine: What Are We Talking About?
    Eddy, David
    VALUE IN HEALTH, 2009, 12 : S6 - S7